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Abstract. The pineal gland is a complex neuroendocrine organ which is under 
photoneuroendocrine control. Previous studies in animals and humans have sug- 
gested reciprocal variations in pineal melatonin biosynthesis and adrenal gluco- 
corticoid output; it remains unclear, however, whether a causal relationship exists 
between these two systems. To address this question, we examined the overnight 
secretory activity of the hypothalamic-pituitary-adrenal (HPA) axis in conjunction 
with acute pharmacological suppression of pineal melatonin biosynthesis in 11 
healthy volunteers. Results of the current study are consistent with the hypothesis 
that melatonin does not function as a tonic inhibitor of the HPA axis on an acute 
basis. 
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The pineal gland is a complex neuroendocrine organ which sits at the interface of the 
blood-brain barrier, where it can release its products into thecerebrospinal fluid and the 
systemic circulation (Pevet, 1982). It is under photoneuroendocrine control, producing 
its major biosynthetic product, N-acetyl-5methoxytryptamine or melatonin, during 
darkness (Lewy, 1982). 
Norepinephrine is the principal regulatory signal for melatonin biosynthesis, stimu- 
lating both /3,- and cy,-adrenergic receptors on the pinealocyte (Klein et al., 1983). This 
leads to activation of the cyclic adenosine monophosphate and inositol phosphate 
second messenger pathways, with synthesis of the enzyme serotonin-N-acetyl- 
transferase (SNAT) and the production of melatonin (Klein et al., 1983; Sugden et al., 
1985). In addition to norepinephrine, a number of neuropeptide systems are known to 
impinge on the pineal gland either through peptidergic projections (e.g., vasopressin 
and oxytocin) or via receptors located on the pinealocyte surface (e.g., vasoactive 
intestinal peptide, substance P) (Ebadi, 1987). The functional effect of these multiple 
neurochemical inputs on the noradrenergic regulation of pineal activity is unknown. 
A variety of animal studies have suggested a relationship between the pineal gland 
and the hypothalamic-pituitary-adrenal (HPA) axis (Wurtman et al., 1959, 1961; 
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Vaughan et al., 1972). Studies in humans have suggested the possibility of an inverse 
association between pineal and adrenal activity in affective illness (Beck-Friis et al., 
1985; Frazer et al., 1986); it is unclear, however, whether thereisacausalrelationship in 
either direction. 
To examine further the possible association between activity of the pineal gland and 
the HPA axis in normal individuals, weexamined the overnight secretory activity ofthe 
HPA axis in conjunction with acute pharmacological suppression of nocturnal mela- 
tonin release. Blockade of nocturnal melatonin release was obtained with the /3- 
adrenergic antagonists propranolol and atenolol. We chose to compare the effects of 
these two agents since propranolol is a nonselective, lipophilic P-adrenergic receptor 
antagonist and therefore blocks both PI- and &-adrenergic receptors centrally and 
peripherally. Atenolol, on the other hand, is a selective fi,-adrenergic receptor, nonlipo- 
philic P-blocker. Therefore, it may be theoretically more selective in blocking the 
peripherally located P,-adrenergic receptors on the pinealocytes while having little 
penetration into the central nervous system. Parenthetically, catecholaminergicstimu- 
lation of pituitary release of adrenocorticotropic hormone (ACTH) appears to occur 
via &-adrenergic receptors, suggesting little effect of atenolol on this mechanism 
(Mezey et al., 1983). 
Methods 
Subjects. Eleven subjects (7 males, 4 females, age range 20-33) were recruited. All subjects were 
interviewed before the study and underwent a complete physical examination to rule out 
significant medical or psychiatric illness. All subjects refrained from using medications, alcohol, 
and caffeine and had been on a regular schedule of 8-9 hours of sleep (10:30-l 1:30 p.m. until 
6:30-7:30 a.m.) for 2 weeks before each study night. 
Procedure. Three separate studies were performed, at least 2 weeks apart from one another. All 
subjects underwent studies in the same order. For study 1, subjects were instructed to collect all 
urinevoidedafter6p.m.,up toandincludingafinalvoidat 1Oa.m. thefollowingmorning. Study2 
involved a urine collection as above. In addition, at 6p.m. duringstudy 2,eachsubject wasgivena 
dose of 60 mg of propranolol. Pulse and blood pressure were then monitored for the next 2 hours. 
At lo:30 p.m., an additional dose of 40 mg of propranolol was given. Pulse and blood pressure 
were again monitored for an hour. Study 3 was similar in format to study 2 with the substitution of 
atenolol for propranolol in dosages of 50 mg and 25 mg at 6 p.m. and lo:30 p.m., respectively. No 
patients reported adverse effects from the dosages of @blockers administered. 
Urine was aliquoted within 2 hours of final collection and frozen at -70 “C until assayed. 
Urinary free cortisol was measured by competitive protein binding assay as previously described 
(Contreras et al., 1986). Intra-assay and interassay variabilities were 7.6% and 12.5%, respec- 
tively. The principal urinary metabolite of melatonin, 6-hydroxymelatonin, was assayed by gas 
chromatography/mass spectrometry, as previously described (Tetsuo et al., 1981). Intra-assay 
and interassay variabilities were < 6%. 
Results 
Acute administration of either 100 mg of propranolol or 75 mgof atenolol resulted in an 
almost complete pharmacological ablation of the nocturnal surge of 6-hydroxy- 
melatonin excretion (baselinemean+SD= 13721+4945ng/TVvs. 1413 f 1138 ng/TV 
on propranolol, p < 0.006, and 2961 + 1850 ng/TV on atenolol,p < 0.006) (Fig. la). 
However, no significant differences were seen in overnight urinary free cortisol 
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excretion between study 1 and either of the two subsequent studies (baseline mean + SD 
= 31*41.~g/TVvs, 35 f 7 pg/TV on propranololand30*3pg/TVonatenolol)(Fig. 16). 
Significant reductions in pulse and blood pressure were noted during the treatment 
nights (Table 1). No discomfort was reported by any subject. 
Fig. la. Effect of acute beta-adrenergic receptor blockade on overnight 
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Fig. lb. Effect of acute beta-adrenergic receptor blockade on overnight 
secretion of cortisol 
60 
1 
Table 1. Effect of beta blockade on heart rate and blood pressure (BP) 
Baseline Propranolol Baseline Atenolol 
Pulse 76f7 56f3t 722 7 55k61 
Systolic BP 114f7 100261 116+ 10 99k61 
Diastolic BP 79+7 69f61 75k 7 65k61 




In the present study, we have shown that acute pharmacological blockade of melatonin 
biosynthesis was not associated with a concomitant rise of overnight cortisolsecretion. 
In addition, we have replicated previous findings that both propranolol and the 
nonlipophilic, P,-selective adrenergic receptor antagonist atenolol produce a dramatic 
reduction of the nocturnal melatoninsurge(Cowenet al., 1983; Arendt et al., 1985). The 
absence of an inverse association between melatonin and cortisol after reduction in 
melatonin secretion is consistent with the hypothesis that melatonin does not function 
as a tonic inhibitor of the HPA axis on an acute basis. 
A variety of studies in animals have suggested an inhibitory effect of melatonin on 
cortisol secretion (Wurtman et al., 1959, 1961; Vaughan et al., 1972). Although the 
mechanism of melatonin-induced decrease of adrenal gland weight was not definitively 
elucidated, data indicating a concomitant decrease in plasma ACTH secretion strongly 
suggest a hypothalamic or pituitary mechanism may be involved (Kinson et al., 1968). 
Investigation of the role of glucocorticoids on pineal biosynthesis has been less 
extensively reported. The definitive presence of glucocorticoid receptors in pinealo- 
cytes has not been noted, although JH-dexamethasone concentrates in the pinealgland 
(Warembourg, 1975). In cell culture, glucocorticoids have been reported to inhibit the 
melatonin increase seen with noradrenergic stimulation (Fevre-Montagne and Abou- 
Samra, 1983). Lipocortin, the tissue mediator of glucocorticoid effects on prostaglan- 
din biosynthesis, is widely distributed throughout the body, including the brain 
(Wallner et al., 1986). In this regard, it is interesting that in wholeorganpinealcultures, 
glucocorticoids appear to inhibit the noradrenergically stimulated release of arachi- 
donic acid, possibly through lipocortindependent inhibition of phospholipase A2 
activity (Demitrack et al., unpublished observations). A possible developmental role 
for glucocorticoids in the modulation of pineal biosynthetic activity has beensuggested 
by the work of Yuwiler (1985), who demonstrated that neonatal exposure to gluco- 
corticoids in the rat produces a reduction of noradrenergically stimulated SNAT 
activity in the adult rat. 
Clinical studies in humans suggest a complex relationship between the pineal and 
adrenal glands. In studies of affectively ill individuals, a number of investigators have 
suggested an inverse relationship between melatonin and cortisol, with a blunting ofthe 
normal nocturnal melatonin rise (Beck-Friis et al., 1983; Frazer et al., 1986), although 
this finding has not been universally replicated (Thompson et al., 1988). In some 
instances, this abnormality appears to persist into the euthymic state (Beck-Friis et al., 
1983), a finding which may be of interest in light of the work of Yuwiler noted above (i.e., 
peristent reduction of nocturnal melatonin may occur as a consequence of repeated 
activation of the HPA axis in early life. Interestingly, acute administration of gluco- 
corticoids to normal subjects has not been reliably shown to produce a reduction in 
melatonin secretion at night (Beck-Friis et al., 1983; Demisch et al., 1987). 
Studies in the other clinical populations with manifest hypercortisolism also suggest 
that the reduction in nocturnal melatonin secretion does not simply occur as a 
consequence of glucocorticoid restraint of pinealocyte function. For example, reports 
of patients with anorexia nervosa (Dalery et al., 1985; Brambilla et al., 1988) or 
Cushing’s syndrome (Young, 1981) demonstrate normal or elevated amplitude of 
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melatonin rhythm. However, in a study of 10 patients with ACTH-producing adeno- 
mas, Werner et al. (1980) reported that the mean nighttime peak ofmelatonin secretion 
was significantly reduced. Parenthetically, Kennedy et al. (1989) have demonstrated a 
blunting of the nocturnal melatonin surge in a population of patients with anorexia 
nervosa or bulimia nervosa who were also significantly depressed, but not in a 
nondepressed group of patients with eating disorders. This suggests that abnormalities 
of the nocturnal melatonin rhythm again may not occur as a simple consequence of 
hypercortisolism alone, but may reflect defects in pineal function that are intrinsic to the 
pathophysiology of the depressed state. 
As mentioned above, a variety of neuropeptide systems impinge on the pineal gland, 
either through peptidergic projections from other brain locations (Buijs and Pevet, 
1980) or via receptors present on the pinealocyte membrane (Ebadi, 1987). As the 
neuropeptide milieu of the cerebrospinal fluid varies significantly in the illness states 
mentioned, such variations may play a role in modulating the pineal response to 
hypercortisolism. 
The findings of this pilot study demonstrate that acute reductions inmelatonin levels 
induced by P-blockers are not associated with concomitant increases in cortisol 
secretion. This is consistent with the hypothesis that in the normal individual melatonin 
does not serve as a tonic inhibitor of cortisol release. It should be noted that the dose of 
propranolol chosen in this study resulted in a mean reduction of melatonin from 
baseline of 90% compared with a mean reduction of 80% with the administration of 
atenolol. While these results are comparable, the possibility cannot be excluded that a 
higher dose of atenolol would have yielded positive results that were otherwise obscured 
by small but significant levels of circulating melatonin. As a corollary finding, it is also of 
interest that acute challenge with propranolol did not appear to affect cortisol secretion. 
As noted previously, catecholamine modulation of HPA axis function may occur via 
direct pituitary stimulation of &-adrenergic receptors. The results obtained in the 
present study would suggest that catecholamines do not tonically stimulate HPA axis 
activity on an acute basis. 
In sum, it remains to be determined whether, in the normal individual, more chronic 
alterations of adrenal activity or biosynthesis of melatonin may be associated with one 
another. Further, associated disturbances of these two systems in pathological states 
such as depression and anorexia nervosa may differ significantly from the normal 
individual and should be interpreted in light of known alterations in other neuro- 
endocrine axes. 
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